Editas Medicine Q2 2024 net loss $67.6M ($0.82/share), cash $318.3M, on track for clinical data by year-end

Editas Medicine, Inc.

2024-Q2 EPS reported -$1.58 revenue$1,649,000

Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.
Cash and equivalents $318.3M as of June 30, 2024 (down from $376.8M Q1); runway into 2026.
R&D expenses $54.2M, up $24.4M driven by reni-cel program and in vivo research.
On track to present additional clinical data from RUBY (SCD) and EdiTHAL (TDT) trials by year-end 2024.
Completed enrollment of adult cohorts for both RUBY and EdiTHAL; adolescent cohort enrolled for RUBY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.